Alluvi, previously known as LY3414901, represents a noteworthy advancement in weight management. This twin -action glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) target agonist shows remarkable impact in early clinical data, with considerable weight loss obser